Abstract
The results obtained from 23 patients suffering small cell lung carcinoma limited to the thorax, treated with 4 cycles of cyclophosphamide, adriamycin, vincristine alternating with cisplatin and VP/16, followed by mediastinal and holocranial prophylactic radiotherapy in patients with a complete response (CR) are here presented. An 87% of global responses were obtained with a 64% rate of RC. The average survival rate was 12 months with an 18% of patients alive two years after treatment. The main toxicity was hematologic and neurologic. Even if this alternating regime produces a high response rate, the results are not superior to those obtained with conventional chemotherapy.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / mortality
-
Carcinoma, Small Cell / radiotherapy
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Etoposide / administration & dosage
-
Etoposide / adverse effects
-
Humans
-
Lomustine / administration & dosage
-
Lomustine / adverse effects
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Lung Neoplasms / radiotherapy
-
Methotrexate / administration & dosage
-
Methotrexate / adverse effects
-
Procarbazine / administration & dosage
-
Procarbazine / adverse effects
-
Remission Induction
-
Time Factors
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
Substances
-
Procarbazine
-
Vincristine
-
Etoposide
-
Lomustine
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin
-
Methotrexate
Supplementary concepts
-
C'MP protocol
-
CAV protocol
-
VP-P protocol